Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

PURPOSE: Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM). PATIENTS AND METHODS: Patients with recurrent GBM who had received one or fewer chemotherapy regimens for progressive disease were eligible. Vorinostat was administered at...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Galanis, Evanthia, Jaeckle, Kurt A., Maurer, Matthew J., Reid, Joel M., Ames, Matthew M., Hardwick, James S., Reilly, John F., Loboda, Andrey, Nebozhyn, Michael, Fantin, Valeria R., Richon, Victoria M., Scheithauer, Bernd, Giannini, Caterina, Flynn, Patrick J., Moore, Dennis F., Zwiebel, James, Buckner, Jan C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2669764/
https://ncbi.nlm.nih.gov/pubmed/19307505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.0694
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados